These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 14565857)

  • 1. Inhibition of HIV-1 in the central nervous system by IFN-alpha2 delivered by an SV40 vector.
    Cordelier P; Calarota SA; Pomerantz RJ; Xiaoshan J; Strayer DS
    J Interferon Cytokine Res; 2003 Sep; 23(9):477-88. PubMed ID: 14565857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trans-activated interferon-alpha2 delivered to T cells by SV40 inhibits early stages in the HIV-1 replicative cycle.
    Cordelier P; Calarota SA; Strayer DS
    J Hematother Stem Cell Res; 2002 Oct; 11(5):817-28. PubMed ID: 12427288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antioxidant enzyme gene delivery to protect from HIV-1 gp120-induced neuronal apoptosis.
    Agrawal L; Louboutin JP; Reyes BA; Van Bockstaele EJ; Strayer DS
    Gene Ther; 2006 Dec; 13(23):1645-56. PubMed ID: 16871233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditional expression of IFN-alpha and IFN-gamma activated by HBV as genetic therapy for hepatitis B.
    Matskevich AA; Cordelier P; Strayer DS
    J Interferon Cytokine Res; 2003 Dec; 23(12):709-21. PubMed ID: 14769147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditional expression of alpha1-antitrypsin delivered by recombinant SV40 vectors protects lymphocytes against HIV.
    Cordelier P; Strayer DS
    Gene Ther; 2003 Dec; 10(26):2153-6. PubMed ID: 14625571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting AIDS in the central nervous system: gene delivery to protect neurons from HIV.
    Cordelier P; Van Bockstaele E; Calarota SA; Strayer DS
    Mol Ther; 2003 Jun; 7(6):801-10. PubMed ID: 12788654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-human immunodeficiency virus type 1 gene therapy in human central nervous system-based cells: an initial approach against a potential viral reservoir.
    Mukhtar M; Duke H; BouHamdan M; Pomerantz RJ
    Hum Gene Ther; 2000 Jan; 11(2):347-59. PubMed ID: 10680847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploiting hepatitis C virus activation of NFkappaB to deliver HCV-responsive expression of interferons alpha and gamma.
    Matskevich AA; Strayer DS
    Gene Ther; 2003 Oct; 10(22):1861-73. PubMed ID: 14502215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 proprotein processing as a target for gene therapy.
    Cordelier P; Zern MA; Strayer DS
    Gene Ther; 2003 Mar; 10(6):467-77. PubMed ID: 12621451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection.
    BouHamdan M; Duan LX; Pomerantz RJ; Strayer DS
    Gene Ther; 1999 Apr; 6(4):660-6. PubMed ID: 10476226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells.
    Lapenta C; Santini SM; Proietti E; Rizza P; Logozzi M; Spada M; Parlato S; Fais S; Pitha PM; Belardelli F
    Virology; 1999 Oct; 263(1):78-88. PubMed ID: 10544084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy using a simian virus 40-derived vector inhibits the development of in vivo human immunodeficiency virus type 1 infection of severe combined immunodeficiency mice implanted with human fetal thymic and liver tissue.
    Goldstein H; Pettoello-Mantovani M; Anderson CM; Cordelier P; Pomerantz RJ; Strayer DS
    J Infect Dis; 2002 May; 185(10):1425-30. PubMed ID: 11992277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protecting neurons from HIV-1 gp120-induced oxidant stress using both localized intracerebral and generalized intraventricular administration of antioxidant enzymes delivered by SV40-derived vectors.
    Louboutin JP; Agrawal L; Reyes BA; Van Bockstaele EJ; Strayer DS
    Gene Ther; 2007 Dec; 14(23):1650-61. PubMed ID: 17914406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.
    Jayan GC; Cordelier P; Patel C; BouHamdan M; Johnson RP; Lisziewicz J; Pomerantz RJ; Strayer DS
    Gene Ther; 2001 Jul; 8(13):1033-42. PubMed ID: 11438838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing HIV-1 Tat-induced neuronal apoptosis using antioxidant enzymes: mechanistic and therapeutic implications.
    Agrawal L; Louboutin JP; Strayer DS
    Virology; 2007 Jul; 363(2):462-72. PubMed ID: 17336361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using gene delivery to protect HIV-susceptible CNS cells: inhibiting HIV replication in microglia.
    Cordelier P; Strayer DS
    Virus Res; 2006 Jun; 118(1-2):87-97. PubMed ID: 16414141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autocrine interferon-beta synthesis for gene therapy of HIV infection: increased resistance to HIV-1 in lymphocytes from healthy and HIV-infected individuals.
    Vieillard V; Lauret E; Maguer V; Jacomet C; Rozenbaum W; Gazzolo L; De Maeyer E
    AIDS; 1995 Nov; 9(11):1221-8. PubMed ID: 8561974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral activity of herpes simplex virus vectors expressing murine alpha 1-interferon.
    Mester JC; Pitha PM; Glorioso JC
    Gene Ther; 1995 May; 2(3):187-96. PubMed ID: 7614249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 Tat neurotoxicity: a model of acute and chronic exposure, and neuroprotection by gene delivery of antioxidant enzymes.
    Agrawal L; Louboutin JP; Reyes BA; Van Bockstaele EJ; Strayer DS
    Neurobiol Dis; 2012 Feb; 45(2):657-70. PubMed ID: 22036626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of HIV replication: a powerful antiviral strategy by IFN-beta gene delivery in CD4+ cells.
    Brule F; Khatissian E; Benani A; Bodeux A; Montagnier L; Piette J; Lauret E; Ravet E
    Biochem Pharmacol; 2007 Sep; 74(6):898-910. PubMed ID: 17662695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.